Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijantimicag.2024.107170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Drug Monitoring-Guided Linezolid Therapy for the Treatment of Multiple Staphylococcal Brain Abscesses in a 3-Month-Old Infant.
Pathogens
December 2024
Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Brain abscesses are invasive infections of the central nervous system with a high level of treatment complexity especially in pediatric patients. Here, we describe a 3-month-old infant with multiple brain abscesses caused by methicillin-susceptible (MSSA). The patient was initially treated with empirical antibiotics (ceftriaxone, metronidazole, vancomycin).
View Article and Find Full Text PDFThe Changes in the Antibiotic Resistance of , , and in the Clinical Isolates of a Multiprofile Hospital over 6 Years (2017-2022).
J Clin Med
January 2025
Department of Medical Biology, Faculty of Nursing and Midwifery, Wroclaw Medical University, 50-368 Wroclaw, Poland.
The growing resistance of bacteria to antibiotics is a serious problem in health care. The present study aims to assess the drug resistance of , , and isolated from infections in a multispecialty hospital over a 6-year period. Identification and antimicrobial susceptibility testing were performed using the VITEK2 automated system (Biomerieux).
View Article and Find Full Text PDFFirst Detection and Genomic Characterization of Linezolid-Resistant Clinical Isolates in Bulgaria.
Microorganisms
January 2025
Department of Medical Microbiology "Corr. Mem. Prof. Ivan Mitov, MD, DMSc", Faculty of Medicine, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria.
Linezolid is an oxazolidinone antibiotic and is considered a last-resort treatment option for serious infections caused by problematic Gram-positive pathogens, including vancomycin-resistant enterococci. The present study aimed to explore the linezolid resistance mechanisms and genomic characteristics of two vancomycin-susceptible isolates from Bulgaria. The strains designated Efs2503-bg (inpatient from Pleven) and Efs966-bg (outpatient from Varna) were recovered from wounds in 2018 and 2023, respectively.
View Article and Find Full Text PDFSafety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital.
Antibiotics (Basel)
December 2024
Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.
: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (BPaLM).
View Article and Find Full Text PDFAssessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques.
NPJ Antimicrob Resist
December 2024
Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, 98145, USA.
Tuberculosis (TB) killed approximately 1.3 million people in 2022 and remains a leading cause of death from the bacteria Mycobacterium tuberculosis (M.tb); this number of deaths was surpassed only by COVID-19, caused by the SARS-CoV-2 virus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!